Peptide status tracker

Where each peptide stands with the FDA, and the most recent official record about it.

Sources last checked .

Which sources?
  • ClinicalTrials.gov API v2: November 17, 2026
  • PubMed E-utilities: November 17, 2026
  • Federal Register API: November 17, 2026
  • Drugs@FDA via openFDA: November 17, 2026
  • FDA official pages and 503A category list: November 17, 2026

October 30, 2026: HHS draft policy on compounding six peptides →

October 30, 2026: HHS draft policy on compounding six peptides

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS says the policy is not binding and may be revisited if safety or quality problems arise.↗

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The policy applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.↗

FDA’s compounding review of these peptides, in detail →

All 116 profiles

FDA-approved
Approval reported abroad
In clinical trials
Not FDA-approved

Select a column heading to sort.

5-Amino-1MQ5-Amino-1-methylquinoliniumNot a peptide: a small molecule often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied only in cells and animalsFDA’s compounding safety-risk page is last updated; it does not list 5-Amino-1MQ.Animal and lab only
AbaloparatideTymlosFDA-approved↗↗As Tymlos for osteoporosisDailyMed publishes the Tymlos label version cited on this page.Large human trials
AfamelanotideScenesseFDA-approved↗↗As Scenesse for erythropoietic protoporphyriaDailyMed publishes the Scenesse label version cited on this page.Smaller human trials
AlbiglutideTanzeumFDA-approved↗As Tanzeum; discontinuedFDA approves Tanzeum, application 125431, according to Drugs@FDA.Large human trials
AmycretinZenagamtideIn clinical trials↗↗Not FDA-approvedClinicalTrials.gov first posts AMBITION 1 and AMBITION 2, Phase 3 zenagamtide trials in type 2 diabetes.Smaller human trials
AOD-9604AOD-9604 acetateNot FDA-approved↗↗↗FDA advised against adding it to the compounding listFDA’s compounding safety-risk page, as last updated, lists AOD-9604 among withdrawn nominations with safety concerns.Limited human data
ApraglutideIn clinical trials↗↗Not FDA-approvedClinicalTrials.gov record NCT07742735 updatedSmaller human trials
AvexitideIn clinical trials↗↗↗Not FDA-approvedClinicalTrials.gov record NCT06747468 updatedSmaller human trials
AviptadilZyesamiIn clinical trials↗↗↗Not FDA-approved; studied in clinical trialsFDA’s compounding safety-risk page is last updated; it does not list aviptadil.Large human trials
BivalirudinAngiomaxFDA-approved↗↗As Angiomax and generics as an anticoagulant during coronary proceduresDailyMed publishes the bivalirudin label version cited on this page.Large human trials
BPC-157Body protection compound 157, BepecinNot FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionLimited human data
BremelanotideVyleesi, PT-141FDA-approved↗↗As Vyleesi for HSDD in premenopausal womenU.S. label revised (DailyMed version 2)Large human trials
CagrilintideAM833, CagriSemaIn clinical trials↗↗↗Not FDA-approvedFDA’s page on unapproved GLP-1 drugs, which says cagrilintide cannot be used in compounding, is updated, as shown by its content-current date.Large human trials
Calcitonin salmonMiacalcin, Salmon calcitoninFDA-approved↗↗As Miacalcin for Paget’s disease, high blood calcium and osteoporosisDrugs@FDA application ANDA216996Smaller human trials
CarfilzomibKyprolisFDA-approved↗↗As Kyprolis for relapsed or refractory multiple myelomaDrugs@FDA application ANDA209526Large human trials
CerebrolysinNot a single peptide: a mixture often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied in clinical trialsClinicalTrials.gov record NCT07846488 updatedSmaller human trials
CetrorelixCetrotideFDA-approved↗↗As Cetrotide for use in controlled ovarian stimulationDrugs@FDA application ANDA218740Smaller human trials
CibinetideARA 290In clinical trials↗↗↗Not FDA-approved; studied in clinical trialsFDA’s compounding safety-risk page is last updated; it does not list cibinetide.Smaller human trials
CJC-1295CJC-1295 DACNot FDA-approved↗Named as an unapproved new drug in a federal enforcement caseFDA’s compounding safety-risk page, as last updated, lists CJC-1295 among withdrawn nominations with safety concerns.Smaller human trials
CotadutideIn clinical trials↗↗Not FDA-approved; studied in clinical trialsClinicalTrials.gov record NCT05364931 updatedLarge human trials
DalbavancinDalvanceFDA-approved↗↗As Dalvance for acute bacterial skin infectionsDrugs@FDA application ANDA219604Large human trials
DaptomycinCubicin, Cubicin RFFDA-approved↗↗As Cubicin RF for skin infections and S. aureus bloodstream infectionsDailyMed publishes the Cubicin RF label version cited on this page.Large human trials
DasiglucagonZegalogueFDA-approved↗↗As Zegalogue for severe low blood sugar; discontinuedDailyMed publishes the Zegalogue label version cited on this page.Smaller human trials
DegarelixFirmagonFDA-approved↗↗As Firmagon for advanced prostate cancerDailyMed publishes the Firmagon label version cited on this page.Large human trials
DesmopressinDDAVPFDA-approved↗↗As DDAVP for diabetes insipidus and bedwettingDrugs@FDA application ANDA219981Smaller human trials
DifelikefalinKorsuvaFDA-approved↗↗As Korsuva for kidney-disease itching in adults on hemodialysisDrugs@FDA application ANDA220919Large human trials
DihexaDihexa acetate, PNB-0408Not FDA-approved↗No FDA approval reported; FDA has no human exposure data for itFDA’s compounding safety-risk page, as last updated, lists dihexa acetate among withdrawn nominations.Animal and lab only
DulaglutideTrulicityFDA-approved↗↗As TrulicityDailyMed publishes the Trulicity label version cited on this page.Large human trials
EfinopegdutideHM12525A, JNJ-64565111Not FDA-approved↗↗No FDA approval reported; studied in clinical trialsClinicalTrials.gov record NCT06465186 updatedSmaller human trials
EfpeglenatideHM11260CIn clinical trials↗↗↗Not FDA-approvedClinicalTrials.gov record NCT06174779 updatedLarge human trials
ElamipretideSS-31, MTP-131FDA-approved↗↗As Forzinity under accelerated approval for Barth syndromeThe 4TAZPower trial record is updated on ClinicalTrials.gov, listing the trial as recruiting.Smaller human trials
EloralintideIn clinical trials↗↗Not FDA-approvedClinicalTrials.gov record NCT07935304 updatedSmaller human trials
EmideltideDSIP, Delta sleep-inducing peptideNot FDA-approved↗Under FDA review for pharmacy compoundingFDA committee met on seven peptide-related groups of bulk drug substancesSmaller human trials
EnfuvirtideFuzeonFDA-approved↗As Fuzeon for HIV-1; discontinuedFDA approves Fuzeon, NDA 021481, according to Drugs@FDA.Large human trials
EpitalonAEDG, EpithalonNot FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionLimited human data
EptifibatideIntegrilinFDA-approved↗↗As Integrilin and generics for acute coronary syndrome and PCIDailyMed publishes the eptifibatide label version cited on this page.Large human trials
EtelcalcetideParsabivFDA-approved↗↗As Parsabiv for secondary hyperparathyroidism on hemodialysisDailyMed publishes the Parsabiv label version cited on this page.Large human trials
ExenatideByetta, BydureonFDA-approved↗↗↗↗↗As Byetta, Bydureon and generic exenatideFDA publishes its determination that Byetta was not withdrawn from sale for reasons of safety or effectiveness.Large human trials
Follistatin-344FS344Not a peptide: a protein, larger than a peptide, often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied as a gene therapy in small trialsNo dated official record yetLimited human data
FOXO4-DRINot FDA-approved↗↗No FDA approval reported; studied only in cells and animalsNo dated official record yetAnimal and lab only
Gallium Ga 68 dotatateNETSPOT, Ga-68 DOTATATEFDA-approved↗↗As NETSPOT for PET imaging of neuroendocrine tumorsDailyMed publishes version 23 of the NETSPOT label, the version cited here.Limited human data
GanirelixGanirelix acetateFDA-approved↗↗As ganirelix acetate for use in controlled ovarian hyperstimulationDailyMed publishes the ganirelix label version cited on this page.Large human trials
GHK-CuCopper tripeptide-1, GHK copperNot FDA-approved↗Under FDA review for pharmacy compounding by non-injectable routesFDA’s 503A list places GHK-Cu, except injectable routes, back under evaluation for pharmacy compoundingSmaller human trials
GHRP-2Pralmorelin, Growth hormone-releasing peptide 2Not FDA-approved↗No FDA approval reported; on FDA’s compounding safety-risk list (category 2)FDA’s 503A nominations list, as last updated, places GHRP-2 in category 3.Smaller human trials
GHRP-6Growth hormone-releasing peptide 6Not FDA-approved↗No FDA approval reported; on FDA’s compounding safety-risk list (category 2)FDA’s compounding safety-risk page, as last updated, keeps GHRP-6 in category 2.Limited human data
Glatiramer acetateCopaxoneNot a single peptide: a mixture often looked up alongside peptidesFDA-approved↗↗As Copaxone for relapsing multiple sclerosisDailyMed publishes version 36 of the Copaxone label, the version cited here.Large human trials
GlepaglutideIn clinical trials↗↗Not FDA-approvedClinicalTrials.gov record NCT07197944 updatedSmaller human trials
GlucagonGvoke VialDx, GvokeFDA-approved↗↗↗↗As Gvoke, Baqsimi and other glucagon productsDailyMed publishes the Gvoke and Gvoke VialDx label version cited on this page.Smaller human trials
GonadorelinFactrel, LutrepulseFDA-approved↗↗As Factrel and Lutrepulse; discontinuedFDA approves Lutrepulse (gonadorelin acetate), NDA 019687, according to Drugs@FDA.Limited human data
GoserelinZoladexFDA-approved↗↗As Zoladex for prostate cancer, breast cancer and endometriosisDailyMed publishes the Zoladex label version cited on this page.Large human trials
HexarelinExamorelinNot FDA-approved↗↗No FDA approval reportedFDA’s compounding safety-risk page is last updated; it does not list hexarelin.Smaller human trials
HistrelinSupprelin LAFDA-approved↗↗As Supprelin LA for central precocious pubertyDailyMed publishes the Supprelin LA label version cited on this page.Limited human data
HumaninNot FDA-approved↗↗No FDA approval reported; studied only in the laboratoryNo dated official record yetAnimal and lab only
IcatibantFirazyrFDA-approved↗↗As Firazyr for acute attacks of hereditary angioedemaDailyMed publishes the Firazyr label version cited on this page.Smaller human trials
IGF-1 LR3Long R3 IGF-I, Long-(Arg3) insulin-like growth factor-INot a peptide: a protein, larger than a peptide, often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied only in cells and animalsNo dated official record yetAnimal and lab only
Insulin glargine-aldyLanglaraFDA-approved↗↗↗As LanglaraU.S. label revised (DailyMed version 7)Large human trials
IpamorelinIpamorelin acetateNot FDA-approved↗Named as an unapproved new drug in a federal enforcement caseFDA’s compounding safety-risk page, as last updated, lists ipamorelin acetate in category 2 under the 503B interim policy and among withdrawn nominations.Smaller human trials
Kisspeptin-10Not FDA-approved↗↗↗On FDA’s compounding safety-risk list (category 2)FDA’s Pharmacy Compounding Advisory Committee votes 11 to 0 against placing kisspeptin-10 on the list.Limited human data
KPVLys-Pro-ValNot FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionAnimal and lab only
LanreotideLanreotide acetate, Somatuline DepotFDA-approved↗↗↗↗As Somatuline Depot and other lanreotide productsDrugs@FDA application ANDA218217Smaller human trials
LarazotideLarazotide acetateIn clinical trials↗↗↗Not FDA-approved; studied in clinical trialsFDA’s compounding safety-risk page is last updated; it does not list larazotide.Large human trials
LeuprolideLeuprolide acetate, LupronFDA-approved↗↗↗↗↗↗As Lupron, Eligard, Vobrig and other leuprolide productsFDA approves Vobrig for central precocious puberty in children.Limited human data
LinaclotideLinzessFDA-approved↗↗As LinzessU.S. label revised (DailyMed version 40)Large human trials
LiraglutideSaxenda, VictozaFDA-approved↗↗↗↗As Victoza, Saxenda and generic versionsDailyMed publishes the liraglutide label version cited on this page.Large human trials
LixisenatideSoliqua 100/33, AdlyxinFDA-approved↗↗↗As Adlyxin and in Soliqua 100/33DailyMed publishes the Soliqua 100/33 label version cited on this page.Large human trials
LL-37Cathelicidin LL-37, RopocamptideNot FDA-approved↗No FDA approval reported; on FDA’s compounding safety-risk listFDA’s compounding safety-risk page, as last updated, lists cathelicidin LL-37 among withdrawn nominations with safety concerns.Smaller human trials
Lutetium Lu 177 dotatateLutatheraFDA-approved↗↗As Lutathera for gastroenteropancreatic neuroendocrine tumorsDrugs@FDA application ANDA217060Smaller human trials
Maridebart cafraglutideMariTide, AMG 133In clinical trials↗↗↗Not FDA-approvedThe retained ClinicalTrials.gov record of MARITIME-1 lists the trial as active, not recruiting.Large human trials
MazdutideIBI362, LY3305677Approval reported abroad↗↗China: approval reported by local government sourcesFDA’s page on unapproved GLP-1 drugs, which names mazdutide, is updated, as shown by its content-current date.Large human trials
MecaserminIncrelexNot a peptide: a protein, larger than a peptide, often looked up alongside peptidesFDA-approved↗↗As Increlex for severe primary IGF-1 deficiency in childrenDailyMed publishes version 4 of the Increlex label, the version cited here.Limited human data
Melanotan IINot FDA-approved↗No FDA approval reported; on FDA’s compounding safety-risk listFDA’s compounding safety-risk page, as last updated, lists Melanotan II among withdrawn nominations with safety concerns.Smaller human trials
MetreleptinMyaleptNot a peptide: a protein, larger than a peptide, often looked up alongside peptidesFDA-approved↗↗As Myalept for generalized lipodystrophyDailyMed publishes version 18 of the Myalept label, the version cited here.Limited human data
MK-677Ibutamoren, Ibutamoren mesylateNot a peptide: a small molecule often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; on FDA’s compounding safety-risk list (category 2)FDA’s Pharmacy Compounding Advisory Committee votes 13 to 1 against placing ibutamoren mesylate on the 503A bulks list.Large human trials
MotixafortideAphexdaFDA-approved↗↗As Aphexda for stem cell mobilization in multiple myelomaDailyMed publishes the Aphexda label version cited on this page.Smaller human trials
MOTS-cMOTS-C, Mitochondrial open reading frame of the 12S rRNA-cNot FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionAnimal and lab only
NafarelinSynarelFDA-approved↗↗As Synarel for central precocious puberty and endometriosisDailyMed publishes the Synarel label version cited on this page.Smaller human trials
NesiritideNatrecorNot FDA-approved↗↗FDA approval withdrawn in 2020 after the product left the marketFDA’s withdrawal of Natrecor’s approval takes effect, according to its May 14, 2020 Federal Register notice.Large human trials
OctreotideOctreotide acetate, SandostatinFDA-approved↗↗↗↗↗As Sandostatin and other octreotide productsFDA recall report D-0519-2026Smaller human trials
OrforglipronFoundayoNot a peptide: a small molecule often looked up alongside peptidesFDA-approved↗↗As Foundayo for weight reduction in adultsDailyMed publishes version 10 of the Foundayo label, the version cited here.Large human trials
OxytocinPitocinFDA-approved↗↗As Pitocin for labor and bleeding after birthDailyMed publishes the Pitocin label version cited on this page.Large human trials
PalopegteriparatideYorvipathFDA-approved↗↗As Yorvipath for hypoparathyroidism in adultsDailyMed publishes the Yorvipath label version cited on this page.Smaller human trials
PasireotideSigniforFDA-approved↗↗As Signifor for Cushing’s diseaseDailyMed publishes the Signifor label version cited on this page.Smaller human trials
PEG-MGFMechano growth factor pegylated, Mechano growth factorNot FDA-approved↗↗No FDA approval reported; FDA has no human exposure data for itFDA’s updated 503A category lists keep mechano growth factor in category 3.Animal and lab only
PegcetacoplanEmpaveli, SyfovreFDA-approved↗↗As Empaveli for PNH and two complement-driven kidney diseasesDailyMed publishes the Empaveli label version cited on this page.Smaller human trials
PeginesatideOmontys, Peginesatide acetateNot FDA-approved↗↗FDA approval withdrawn in 2019 at the company’s request, after a 2013 recallFDA’s withdrawal of approval of NDA 202799 takes effect, at the company’s request.Large human trials
PemvidutideALT-801In clinical trials↗↗Not FDA-approvedThe retained ClinicalTrials.gov record of a Phase 3 trial in MASH lists it as recruiting.Smaller human trials
PetrelintideZP8396In clinical trials↗↗↗Not FDA-approvedThe retained ClinicalTrials.gov records of ZUPREME-4 and a third Phase 3 trial list them as recruiting.Large human trials
PlecanatideTrulanceFDA-approved↗↗As TrulanceDailyMed publishes the Trulance label version cited on this page.Large human trials
PramlintideSymlinPen, SymlinFDA-approved↗↗As SymlinDailyMed publishes the Symlin label version cited on this page.Large human trials
RetatrutideLY3437943In clinical trials↗↗↗Not FDA-approvedFDA’s page on unapproved GLP-1 drugs, which says retatrutide cannot be used in compounding, is updated, as shown by its content-current date.Large human trials
RusfertideMimryloFDA-approved↗↗As Mimrylo for erythrocytosis in polycythemia veraDailyMed publishes the Mimrylo label version cited on this page.Smaller human trials
SecretinChiRhoStim, Human secretinFDA-approved↗↗As ChiRhoStim for pancreatic and gastrinoma testingDailyMed publishes the ChiRhoStim label version cited on this page.Smaller human trials
SelankSelank acetateNot FDA-approved↗No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nominationFDA’s compounding safety-risk page, as last updated, lists selank acetate among withdrawn nominations with possible safety risks.Limited human data
SemaglutideWegovy, OzempicFDA-approved↗↗↗↗As Ozempic, Rybelsus and WegovyFDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.Large human trials
SemaxNot FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionLimited human data
SermorelinGerefNot FDA-approved↗↗FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectivenessFDA publishes its determination that Geref was not withdrawn from sale for reasons of safety or effectiveness.Limited human data
SetmelanotideImcivreeFDA-approved↗↗As Imcivree for specific rare causes of obesityDailyMed publishes the Imcivree label version cited on this page.Smaller human trials
SLU-PP-332Not a peptide: a small molecule often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied only in cells and animalsNo dated official record yetAnimal and lab only
SurvodutideBI 456906In clinical trials↗↗↗Not FDA-approvedFDA’s page on unapproved GLP-1 drugs, which names survodutide among drugs sold with false research-use labels, is updated, as shown by its content-current date.Large human trials
TB-500N-terminal acetylated 17-23 fragment of thymosin beta-4Not FDA-approved↗HHS draft policy: one of six peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement actionAnimal and lab only
TeduglutideGattexFDA-approved↗↗As Gattex for short bowel syndromeDailyMed publishes the Gattex label version cited on this page.Smaller human trials
TeriparatideForteoFDA-approved↗↗↗↗↗↗As Forteo and other teriparatide productsFDA approves another generic teriparatide application (ANDA214412), according to Drugs@FDA.Large human trials
TerlipressinTerlivazFDA-approved↗↗As Terlivaz for hepatorenal syndromeDailyMed publishes the Terlivaz label version cited on this page.Large human trials
TesamorelinEgriftaFDA-approved↗↗As Egrifta for HIV-associated abdominal fatDailyMed publishes the Egrifta SV label version cited on this page.Large human trials
TesofensineNS2330Not a peptide: a small molecule often looked up alongside peptidesNot FDA-approved↗↗No FDA approval reported; studied in clinical trialsClinicalTrials.gov record NCT03149445 updatedSmaller human trials
ThymopentinTimunoxNot FDA-approved↗↗No FDA approval reported; studied in clinical trialsClinicalTrials.gov record NCT00002049 updatedLarge human trials
Thymosin alpha-1ThymalfasinNot FDA-approved↗↗↗FDA advised against adding it to the compounding listFDA’s compounding safety-risk page, as last updated, lists thymosin alpha-1 among withdrawn nominations with safety concerns.Smaller human trials
Thymosin beta-4Not FDA-approved↗↗No FDA approval reportedFDA’s compounding safety-risk page, as last updated, lists the TB-500 fragment but not thymosin beta-4 itself.Smaller human trials
TirzepatideZepbound, MounjaroFDA-approved↗↗↗As Mounjaro and ZepboundFDA’s page on unapproved GLP-1 drugs is updated, as shown by its content-current date.Large human trials
TriptorelinTrelstarFDA-approved↗↗As Trelstar for advanced prostate cancerDailyMed publishes the Trelstar label version cited on this page.Large human trials
TrofinetideDaybueFDA-approved↗↗As Daybue for Rett syndromeDailyMed publishes the Daybue label version cited on this page.Smaller human trials
VasopressinVasostrictFDA-approved↗↗As Vasostrict for vasodilatory shockDailyMed publishes the Vasostrict label version cited on this page.Limited human data
VK2735In clinical trials↗↗↗Not FDA-approvedClinicalTrials.gov record NCT07868835 updatedSmaller human trials
VosoritideVoxzogoFDA-approved↗↗As Voxzogo under accelerated approval for achondroplasiaDailyMed publishes the Voxzogo label version cited on this page.Smaller human trials
ZiconotidePrialtFDA-approved↗↗As Prialt for severe chronic painDailyMed publishes the Prialt label version cited on this page.Smaller human trials
ZilucoplanZilbrysqFDA-approved↗↗As Zilbrysq for generalized myasthenia gravisDailyMed publishes the Zilbrysq label version cited on this page.Smaller human trials

Status describes what the cited official records say about U.S. approval. It does not say whether a product is safe, legal for a particular use, or available. Approval applies to specific products and uses; open a profile for the details and sources. How we work →